10x Genomics’ (TXG) Sell (E+) Rating Reaffirmed at Weiss Ratings

10x Genomics (NASDAQ:TXG)‘s stock had its “sell (e+)” rating reaffirmed by investment analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

A number of other research firms also recently commented on TXG. Morgan Stanley dropped their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday, August 12th. Stephens restated an “overweight” rating and set a $14.00 price objective on shares of 10x Genomics in a report on Thursday, May 15th. JPMorgan Chase & Co. dropped their price objective on 10x Genomics from $12.00 to $9.00 and set a “neutral” rating for the company in a report on Friday, May 9th. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $13.54.

10x Genomics Stock Performance

Shares of TXG opened at $14.01 on Friday. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The stock has a fifty day moving average of $12.92 and a two-hundred day moving average of $10.69. The company has a market capitalization of $1.74 billion, a PE ratio of -20.01 and a beta of 2.03.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Adam Taich sold 22,315 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,149 shares of company stock valued at $539,865. Company insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its stake in shares of 10x Genomics by 8.1% in the 2nd quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock valued at $160,871,000 after purchasing an additional 1,046,390 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of 10x Genomics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company’s stock valued at $97,061,000 after purchasing an additional 184,537 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after purchasing an additional 4,987,195 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of 10x Genomics by 12.2% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock valued at $69,688,000 after purchasing an additional 654,597 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. raised its stake in shares of 10x Genomics by 12.1% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock valued at $69,532,000 after purchasing an additional 646,997 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.